UCB SA (UCB.BR) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. UCB.BR files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 5.80% | 30.00% | Pass |
| Interest-bearing investments | 5.85% | 30.00% | Pass |
| Non-permissible income | 0.59% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 13.37% | 33.00% | Pass |
| Interest-bearing investments | 13.48% | 33.00% | Pass |
| Non-liquid assets | 79.19% | at least 20.00% | Pass |
| Non-permissible income | 0.59% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 13.37% | 33.33% | Pass |
| Cash + interest-bearing securities | 13.48% | 33.33% | Pass |
| Accounts receivable | 20.81% | 33.33% | Pass |
| Non-permissible income | 0.59% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 13.37% | 33.33% | Pass |
| Cash + interest-bearing securities | 13.48% | 33.33% | Pass |
| Accounts receivable | 20.81% | 50.00% | Pass |
| Non-permissible income | 0.59% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 5.70% | 33.00% | Pass |
| Cash + interest-bearing securities | 5.75% | 33.00% | Pass |
| Accounts receivable | 3.13% | 33.00% | Pass |
| Non-permissible income | 0.59% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 6.80% | 33.00% | Pass |
| Cash + interest-bearing securities | 6.86% | 49.00% | Pass |
| Accounts receivable | 3.73% | 49.00% | Pass |
| Non-permissible income | 0.59% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 6.80% | 33.33% | Pass |
| Cash + interest-bearing securities | 6.86% | 33.33% | Pass |
| Accounts receivable | 10.59% | 49.00% | Pass |
| Non-permissible income | 0.59% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 31.80 | NEUTRAL |
| Stochastic %K (14) | 9.62 | BUY |
| CCI (20) | -245.12 | BUY |
| Williams %R (14) | -90.38 | BUY |
| MACD (12,26,9) | -0.60 | SELL |
| ROC (10) | -8.70 | SELL |
| Momentum (10) | -19.50 | SELL |
| EMA (10) | 213.92 | SELL |
| SMA (10) | 215.65 | SELL |
| EMA (20) | 217.97 | SELL |
| SMA (20) | 217.20 | SELL |
| EMA (30) | 221.63 | SELL |
| SMA (30) | 220.27 | SELL |
| EMA (50) | 227.57 | SELL |
| SMA (50) | 230.50 | SELL |
| EMA (100) | 235.43 | SELL |
| SMA (100) | 238.47 | SELL |
| EMA (200) | 238.87 | SELL |
| SMA (200) | 245.92 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
